Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jason Weatherald, Louise Bondeelle, Marie-Camille Chaumais, Christophe Guignabert, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Philippe Rousselot, Marc Humbert, Anne Bergeron, David Montani. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020 Year: 2020 Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Experience of using Janus kinase inhibitors in COVID-19 Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021 A patient with a lazarus effect on tyrosine kinase inhibition Source: Virtual Congress 2020 – Lung cancer grand round Year: 2020 Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019 Year: 2019 Role of p38 mitogen-activated protein kinase in trauma/hemorrhage and subsequent peumococcal pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Tyrosine kinase inhibition of human pulmonary fibroblast migration Source: Eur Respir J 2005; 26: Suppl. 49, 101s Year: 2005 Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004 Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Kinase inhibitors Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017 Year: 2017 Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis Source: ERS Lung Science Conference 2020 Year: 2020 Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed Source: Eur Respir J 2013; 41: 3-4 Year: 2013